Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

NCT00468767 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: Vernakalant Injection 20 mg/mL

Sponsor

Advanz Pharma

Collaborators

[object Object]